A sales reset shows early signs of success
- Q2 2026 results lowered fears about the U.S. sales force change, leading management to raise full-year guidance.
- Technology and surgical sales jumped 21.5% globally, helped by the new ROSA Shoulder launch.
- U.S. Knees growth remains slow at 1.4%, but U.S. Hips grew a stronger 5.9%.
- International sales face pressure, with a 20% drop in China dragging down the overseas knee business.
A smoother transition
Zimmer Biomet is handling a major internal change better than expected. In Q2 2026, management said the U.S. sales force conversion is causing less customer disruption than initially feared. The company raised its full-year organic constant currency revenue growth guidance to a range of 2.25% to 3.25%, up from the previous 1% to 3% target.
The bull case focuses on this smooth transition and strong technology adoption. New products like the ROSA Shoulder and an iodine-coated hip in Japan are winning market share. Heavy investments in the sales team are starting to improve productivity, setting the stage for a cleaner run rate in 2027.
The bear case shifts from U.S. execution risks to international problems. International knee sales fell 1.5% in Q2, heavily dragged down by a 20% decline in China. While China is a small portion of total revenue, persistent weakness in emerging markets could offset the hard-won gains in the United States.
Implants, instruments, and surgeon relationships
Zimmer Biomet makes money by designing, making, and selling products for musculoskeletal care. In plain English, that means hips, knees, trauma products, sports medicine tools, bone cement, surgical products, and digital systems that help surgeons plan and place implants.
The business benefits from aging patients and active older adults who need joint and bone care. These procedures depend heavily on surgeon trust. That makes the sales channel very important, because reps help hospitals and surgeons get the right products and tools in the operating room.
The company is now changing that sales channel in the U.S. It has started a multi-year plan to convert large portions of its U.S. sales force from independent agents into Zimmer Biomet employees. The goal is more dedicated coverage and more product specialization.
Capital allocation has also shifted. Management paused new acquisitions in 2026 to focus on integrating recent deals and fixing the sales model. In the near term, the company plans to prioritize the return of capital to shareholders over acquisitions.
Where the product bets sit
Knees
Knees are the largest product category. U.S. growth was sluggish at 1.4% in Q2 2026, and international sales declined slightly due to weakness in China.
Hips
Hips are a core joint franchise. Q2 2026 global sales grew 5.1%, with strong U.S. growth of 5.9% and success from new iodine-coated hips in Japan.
S.E.T.
S.E.T. means Sports Medicine, Extremities, and Trauma. It grew 3.4% organically in Q2 2026, helped by the Paragon 28 acquisition.
ROSA robotics and Technology
The Technology and Data category grew 21.5% globally in Q2 2026, driven by record capital sales of ROSA systems, including the new ROSA Shoulder.
Monogram mBôs
Monogram adds a semi and fully autonomous robotics platform. The upside is high, but commercialization depends on regulatory clearance and surgeon adoption.
Q1 2026 sales mix
Shares are based on Q1 2026 net sales by product category from the Form 10-Q. Knees and Hips remain the core businesses.
What could go wrong
Sales force conversion disruption
Medium impact · Medium oddsZimmer Biomet is converting much of its U.S. sales force to employees. While early results are better than expected, accelerating this transition in new territories could still trigger localized market share losses or surgeon pushback.
International market weakness
Medium impact · High oddsExposure to macroeconomic and geopolitical dynamics in China caused a 20% decline in that market during Q2 2026. This dragged down the entire international knee business.
Monogram robotics commercialization
Medium impact · Medium oddsThe Monogram mBôs platform could make Zimmer Biomet stronger in autonomous robotics. But the product must clear demanding regulatory steps and prove it can win surgeon trust.
CFO succession
Medium impact · Medium oddsCFO Suky Upadhyay departed, leaving an interim leader while the company searches for a replacement. A slow search could raise questions about capital allocation strategy.
In one breath
What does Zimmer Biomet do?
Zimmer Biomet sells orthopedic implants and related surgical products. Its main categories are Knees, Hips, S.E.T., and Technology and Data.
Why is the U.S. sales force change important?
The company is moving many U.S. sales people from independent agent status to employee status. This can improve focus over time, but it carries the risk of disrupting surgeon relationships.
How is the company performing in 2026?
The transition is going better than expected. In Q2 2026, management raised full-year organic revenue guidance to a range of 2.25% to 3.25%, helped by strong technology and hip sales.
